NCI National Clinical Trials Network (NCTN) Program Guidelines

PART 2: Submission of New/Competing Application Section III.B.2.4 – Review Criteria
Network Lead Academic Participating Site
2.4 Lead Academic Participating Site Review Criteria
Only the review criteria described below (and the Additional Review Criteria – Overall listed
in Part 2 – Section III.B.3.) will be considered in the review process. As part of the NIH
mission, all applications submitted to the NIH in support of biomedical and behavioral
research are evaluated for scientific and technical merit through the NIH peer review
system.
2.4.1 Overall Impact - Overall
Reviewers will provide an overall impact/priority score to reflect their assessment of
the likelihood for the proposed Network Lead Academic Participating Site to exert a
sustained, powerful influence on the research field(s) involved, in consideration of the
following review criteria and additional review criteria (as applicable for the proposed
Network Lead Academic Participating Site).
2.4.2 Scored Review Criteria – Overall
Reviewers will consider each of the review criteria below in the determination of
scientific merit, and give a separate score for each. An application does not need to
be strong in all categories to be judged likely to have major scientific impact. For
example, a proposed Network Lead Academic Participating Site that by its nature is
not innovative may be essential to advance a field.
Significance
Does the proposed Network Lead Academic Participating Site help address an
important problem or a critical barrier to progress in the field? If the aims of the
proposed Network Lead Academic Participating Site are achieved, how will scientific
knowledge, technical capability, and/or clinical practice be improved? How will
successful completion of the aims change the concepts, methods, technologies,
treatments, services, or preventative interventions that drive this field?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the proposed
Network Lead Academic Participating Site as well as its plans for collaborations and
collective management? If Early Stage Investigators or New Investigators, or in the
early stages of independent careers, do they have appropriate experience and
training? If established, have they demonstrated an ongoing record of
accomplishments that have advanced their field(s)? Given that NCTN research
projects/trials are collaborative, and regardless of whether the applicants choose to
use the multi-PD/PI option, do the investigators have complementary and integrated
expertise; are their leadership approach, governance and organizational structure
appropriate for the clinical research that the proposed Network Lead Academic
Participating Site is expected to help conduct and manage?
Innovation
Does the application challenge and seek to shift current research or clinical practice
paradigms by utilizing novel theoretical concepts, approaches or methodologies,
instrumentation, or interventions? Are the concepts, approaches or methodologies,
instrumentation, or interventions novel to one field of research or novel in a broad
sense? Is a refinement, improvement, or new application of theoretical concepts,
approaches or methodologies, instrumentation, or interventions proposed?
Page 168 of 241